timothy sykes logo
CLRB Stock Jumps As New Breast Cancer Trial Begins Thumbnail
G Google News

CLRB Stock Jumps As New Breast Cancer Trial Begins

TIM SYKES•UPDATED MAY. 5, 2026, 9:18 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Cellectar Biosciences Inc. stocks have been trading up by 53.0 percent amid strong positive sentiment over its latest oncology advances.

Candlestick Chart

Live Update At 09:18:01 EDT: On Tuesday, May 05, 2026 Cellectar Biosciences Inc. stock [NASDAQ: CLRB] is trending up by 53.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Cellectar Biosciences (CLRB) is trading like a classic high-risk biotech — thin revenues today, big hopes tied to clinical data tomorrow. The daily chart from 2026/04/10 through 2026/05/04 shows CLRB bouncing between roughly $2.50 and $3.00, a tight range with frequent intraday swings. That tells traders there is active interest, but no clear long-term trend yet.

On the balance sheet, Cellectar Biosciences holds about $13.2M in cash against total assets of $14.98M and total liabilities of $5.06M. A current ratio around 3 and quick ratio near 2.8 mean CLRB has a decent near-term cash cushion for operations. Long-term debt is small at just over $300,000, which keeps financial leverage low.

The flip side is the income statement. CLRB posted a quarterly net loss of about $5.3M and negative operating cash flow of about $4.3M. Returns on equity and assets are sharply negative, which is common for early-stage biotechs but still a red flag for anyone overstaying a trade. For active traders, this setup means CLRB is driven far more by headlines and trial progress than by traditional valuation metrics.

Why Traders Are Watching CLRB After The Trial News

Traders are locked in on CLRB because the company just hit a real clinical milestone. Cellectar Biosciences announced it has enrolled the first patient in a Phase 1b trial of CLR 121125 for triple negative breast cancer, a notoriously tough disease with limited options. When a small-cap biotech like CLRB moves a new asset into human testing, the market pays attention — this is where new catalysts start.

The companion update goes deeper. Cellectar Biosciences confirmed that CLR 125, an Auger-emitting radioconjugate, is being tested in relapsed or refractory triple negative breast cancer. The Phase 1b design focuses on tumor uptake, safety, and early signs of efficacy. The big goal is simple but critical: find the right dose to move into Phase 2. For CLRB traders, that makes every data update a potential volatility event.

This trial also matters strategically. CLRB has been known mainly for its lead asset, iopofosine I-131. By pushing CLR 125 into the clinic, Cellectar Biosciences is effectively telling the market that its phospholipid drug conjugate (PDC) radioconjugate platform is broader than just one drug. That platform expansion theme is important; it gives CLRB multiple shots on goal rather than a single binary bet.

You can already see that story reflected in the tape. Intraday, CLRB spiked from the low $3s to above $6 in premarket before settling back into the $4s, a huge volatility burst that active traders live for. Big wicks and wide ranges on the 5‑minute chart show aggressive scalping and fast profit-taking. For day traders, CLRB is now firmly on the radar as a headline-driven momentum name.

More Breaking News

Conclusion

For traders, Cellectar Biosciences sits at the intersection of science and speculation. CLRB does not have pretty earnings or strong margins; it has a pipeline and cash to push that pipeline forward. The new Phase 1b trial of CLR 121125 and CLR 125 in triple negative breast cancer gives the stock a fresh narrative and a clear series of upcoming catalysts around safety, tumor uptake, and early efficacy data.

The balance sheet tells us Cellectar Biosciences has some runway, but the steady quarterly burn means dilution is always a background risk. That is standard in this corner of biotech. What really drives CLRB from here is how the market reacts to each trial update and whether traders see enough momentum to chase the next spike. The recent premarket surge from roughly $3 to above $6 in a few hours shows what this ticker can do when news hits the wire.

Traders in the Tim Sykes community have one core rule for setups like CLRB: respect the volatility and cut losses quickly. As Tim Sykes says, “The market doesn’t care about your hopes, it only cares about price action — react to what the stock is actually doing, not what you wish it would do.” That mindset goes hand in hand with another of his core trading principles: As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. For CLRB, that means treating every move as a trading opportunity, backed by real news but managed with tight risk and clear exit plans.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading CLRB

Millionaire's
POV on CLRB

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”